About Ihab Judeh
This author has yet to write their bio.Meanwhile lets just say that we are proud Ihab Judeh contributed a whooping 5 entries.
Entries by Ihab Judeh
Analysis to Be Presented in Oral Session at the Society of Critical Care Medicine’s 47th Critical Care CongressSAN DIEGO, Feb. 25, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that an abstract, entitled “Effect of Disease Severity on Survival in Patients Receiving Angiotensin II for Vasodilatory Shock,” will be presented at the Society of Critical Care Medicine’s […]
SAN DIEGO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2017 and highlighted recent corporate progress. Recent Corporate Progress In December 2017, GIAPREZA™ (angiotensin II), injection for […]
SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that the first pediatric patient has been treated in LJ501-CRH02, La Jolla’s open-label study of GIAPREZATM (angiotensin II), injection for intravenous infusion, in pediatric patients (ages 2-17) with shock who remain hypotensive despite receiving fluid and current standard-of-care vasopressor therapy. LJ501-CRH02 is an open-label study […]